LacNAc modification in bone marrow stromal cells enhances resistance of myelodysplastic syndrome cells to chemotherapeutic drugs

Chemotherapeutic drugs are used routinely for treatment for myelodysplastic syndrome (MDS) patients but are ineffective in a substantial proportion of patients. Abnormal hematopoietic microenvironments, in addition to spontaneous characteristics of malignant clones, contribute to ineffective hematop...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biochimica et biophysica acta. Molecular cell research 2023-08, Vol.1870 (6), p.119492-119492, Article 119492
Hauptverfasser:	Li, Hongjiao, Ren, Xiaoyue, Pang, Xingchen, Yang, Pengyu, Lu, Yurong, Guan, Feng, Wang, Yi, Li, Xiang
Format:	Artikel
Sprache:	eng
Schlagworte:	BMSCs Bone Marrow Cells - metabolism Drug resistance Hematopoiesis Hematopoietic Stem Cells - metabolism Humans LacNAc MDS Mesenchymal Stem Cells - metabolism Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - genetics Myelodysplastic Syndromes - metabolism β4GalT1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!